ABSTRACT
Diabetic ketoacidosis (DKA) is a form of a hyperglycemic emergency mainly characterized by the triad of hyperglycemia, ketosis, and anion gap metabolic acidosis. DKA may be the initial presentation in approximately 25-40 % of patients with type 1 diabetes. It may also occur in at least 34% of patients with type 2 diabetes. DKA has economic as well as medical implications. This review aims to explore and discuss diabetic ketoacidosis, its pathophysiology, clinical presentation, diagnosis, and management, including nuances in special populations such as pediatrics, obstetrics, and patients with chronic kidney disease.
Subject(s)
Acidosis , Diabetes Mellitus, Type 1 , Diabetes Mellitus, Type 2 , Diabetic Ketoacidosis , Pregnancy , Female , Humans , Child , Diabetic Ketoacidosis/diagnosis , Diabetic Ketoacidosis/therapy , Diabetes Mellitus, Type 2/complications , Acidosis/diagnosis , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/diagnosis , Diabetes Mellitus, Type 1/therapy , Diagnosis, DifferentialABSTRACT
The unpredictability of the coronavirus disease 2019 (COVID-19) pandemic has created an ongoing global healthcare crisis. Implementation of a mass vaccination program to accelerate disease control remains in progress. Although injection site soreness, fatigue, and fever are the most common adverse reactions reported after a COVID-19 vaccination, ipsilateral lymph node enlargement has increasingly been observed. In patients undergoing routine screening and surveillance for breast cancer, interpreting lymphadenopathy (LAP) is challenging in the setting of a recent COVID-19 vaccination. With a growing proportion of the population receiving the vaccine, a multifaceted approach is necessary to avoid unnecessary and costly workup. In this comprehensive review, we summarize the existing literature on COVID-19 vaccine-associated LAP in breast imaging patients.
ABSTRACT
ABBREVIATIONS: AMP = adenosine monophosphate CETP = cholesteryl ester transfer protein FOXO = Forkhead box O GH = growth hormone HDL = high-density lipoprotein IGF-1 = insulin-like growth factor 1 LDL = low-density lipoprotein miRNA = microRNA mTOR = mammalian target of rapamycin SIRT = sirtuin T4 = thyroxine TSH = thyroid-stimulating hormone "The Moving Finger writes; and, having writ, Moves on: nor all thy Piety nor Wit Shall lure it back to cancel half a Line, Nor all thy Tears wash out a Word of it." Omar Khayyam ( 1 ).
Subject(s)
Aging/drug effects , Longevity , Animals , Antioxidants/pharmacology , Endocrine Glands/physiology , Glucuronidase/physiology , Humans , Klotho Proteins , Metformin/pharmacology , TOR Serine-Threonine Kinases/physiologyABSTRACT
Diabetic nephropathy (DN) is a well-described complication of diabetes mellitus and the leading cause of end stage renal disease (ESRD). Although increased albuminuria has been the gold standard for screening, data suggests that renal damage starts long before the onset of clinically apparent increases in macro and even micro-albuminuria. Clinical practice guidelines for the prevention of DN have been traditionally focused on the control of serum glucose, blood pressure and dyslipidemia, with some focus on the renin-angiotensin-aldosterone system (RAAS) as a main target for successful therapy. Recent evidence has led to a better understanding of the underlying mechanisms of the pathophysiology of this disease and suggests that various novels pathways can be targeted to delay and even prevent the progression of DN. Hence a more comprehensive therapeutic approach to therapy is on the horizon, carrying the promise for a more successful and impactful management. This review will highlight new insights into the pathophysiology, clinical aspects and future diagnostic and therapeutic modalities for DN.
Subject(s)
Diabetic Nephropathies , Diabetic Nephropathies/blood , Diabetic Nephropathies/physiopathology , Diabetic Nephropathies/prevention & control , HumansABSTRACT
Introduction. Obese individuals exhibit insulin resistance often leading to adverse health outcomes. When compared with intensive medical therapy, bariatric surgery has shown better outcomes mainly in terms of insulin resistance and glycemic control. Using the Homeostasis Model Assessment of insulin resistance (HOMA-IR), we report herein a case illustrating a drastic improvement in severe insulin resistance after sleeve gastrectomy in the immediate postoperative period. Case Report. A patient with long-standing history of morbid obesity, type 2 diabetes, obstructive sleep apnea, hypertension, and severe insulin resistance (requiring approximately 2 units of insulin per kg per day) was enrolled in the medical weight management program for 6 months during which he lost 40 lbs and his insulin requirements decreased. He then underwent a sleeve gastrectomy and did not require insulin therapy as of postoperative day 1. His HOMA-IR improved by about 76% between day 1 and day 14 postoperatively. Conclusion. Sleeve gastrectomy leads to a drastic improvement in severe insulin resistance as early as the first postoperative day.
Subject(s)
Accidental Falls/prevention & control , Bone Density Conservation Agents/therapeutic use , Vitamin D/analogs & derivatives , Vitamin D/therapeutic use , Accidental Falls/statistics & numerical data , Aged , Hospitalization , Humans , Retrospective Studies , Risk Assessment , Vitamin D/blood , Vitamin D Deficiency/drug therapyABSTRACT
OBJECTIVE: The period of resident turnover in teaching hospitals has been believed by some to lead to worsening of health outcomes or the so-called "July Effect". We sought to study glycemic control in patients admitted to medical floors looking for any adverse outcomes related to a"July effect". METHODS: This is a single-center retrospective cohort study comparing inpatient glycemic control at the start and end of a single academic year (July 2009 to June 2010). A total of 100 inpatients with a diagnosis of diabetes mellitus were included in the first group (Group 1: July to September 2009) and 118 in the second group (Group 2: April to June 2010). Four capillary blood glucose measurements per day from Day 2 to Day 6 of hospitalization, as well as clinical data pertinent to glycemic management were collected. RESULTS: Data analysis showed no significant difference in the overall inpatient glycemic control between the two groups. Mean glucose for Group 1 was 168.67 mg/dL and 168.59 mg/dl for Group 2. 67% of patients in Group 1 and 72.9% in Group 2 were within blood glucose range of 70 - 179 mg/dl, 32% of patients in Group 1 and 52% of patients in Group 2 were within the range of 140 - 179 mg/dL. Hypoglycemia occurred in 17% and 18.6% of patients for Group 1 and 2 respectively. No difference in diabetes treatment ordering practices of residents was detected. CONCLUSION: This study did not show any evidence to support the "July Effect" on overall inpatient glycemic control.
ABSTRACT
BACKGROUND: Adenomectomy is the treatment of choice for ACTH-secreting adenomas. Although the development of ACTH deficiency immediately after adenomectomy suggests surgical success, disease recurrence was reported in patients who developed hypocortisolism postoperatively. In the current study, we examined the value of measuring perioperative plasma ACTH and cortisol levels in predicting disease recurrence of patients with ACTH-secreting adenomas. METHODS: Consecutive patients (n = 55; 41 females, 14 males) with clinical, biochemical, and histological documentation of ACTH-secreting adenomas were investigated after pituitary adenomectomy. All patients were followed with clinical monitoring and frequent measurements of plasma ACTH and serum cortisol levels, and none received glucocorticoids unless or until they developed symptoms of adrenal insufficiency or when their serum cortisol levels were ≤3 µg/dL. RESULTS: Postoperative serum cortisol levels reached ≤3 µg/dL in 46 of 55 and were ≥4 µg/dL in the remaining 9. Simultaneously measured plasma ACTH levels in the latter 9 patients were >40 ng/L when the serum cortisol reached its nadir. In contrast, among the 46 patients who had serum cortisol levels of ≤3 µg/dL, plasma ACTH levels measured simultaneously were ≤20 ng/L in 38 of 46 and >20 ng/L in the remaining 8. During a mean follow-up period of nearly 7 years, patients who had a nadir plasma ACTH of >20 ng/L developed recurrences even though their postoperative serum cortisol levels were ≤3 µg/dL. CONCLUSIONS: Despite profound hypocortisolemia after adenomectomy, a simultaneously measured plasma ACTH level of >20 ng/L in the perioperative period is highly predictive of future recurrence of ACTH-secreting adenomas.
Subject(s)
ACTH-Secreting Pituitary Adenoma/diagnosis , ACTH-Secreting Pituitary Adenoma/surgery , Adenoma/diagnosis , Adenoma/surgery , Adrenocorticotropic Hormone/blood , Perioperative Period , ACTH-Secreting Pituitary Adenoma/blood , Adenoma/blood , Adrenocorticotropic Hormone/analysis , Adult , Female , Humans , Hydrocortisone/analysis , Hydrocortisone/blood , Male , Middle Aged , Neurosurgical Procedures , Prognosis , Recurrence , Reproducibility of Results , Sensitivity and Specificity , Treatment OutcomeABSTRACT
BACKGROUND AND OBJECTIVES: The diagnosis of central adrenal insufficiency (AI) continues to be challenging, especially when it is partial. We have recently demonstrated the value of measuring serum dehydroepiandrosterone sulfate (DHEA-S) in establishing the diagnosis of central AI. The current investigation examined the added value of measuring serum dehydroepiandrosterone (DHEA) levels during low-dose (1 µg) cosyntropin (LDC) stimulation in patients suspected to have central AI. METHODS: Baseline and LDC-stimulated cortisol, DHEA, and DHEA-S were measured preoperatively in 155 consecutive patients with pituitary masses and 63 healthy subjects. Hypothalamic-pituitary adrenal (HPA) function was normal (NL-HPA) in 97 of the patients and was impaired (impaired HPA) in 58 patients. Patients with NL-HPA underwent surgical removal of the sellar masses and received no glucocorticoids before, during, or after surgery. RESULTS: Baseline and LDC-stimulated serum cortisol, DHEA, and DHEA-S in patients with NL-HPA were similar to those of normal subjects. In contrast, patients with impaired HPA had lower baseline and LDC-stimulated serum cortisol, DHEA, and DHEA-S levels. There were 18 subjects in the latter group whose LDC-stimulated serum cortisol levels were greater than 18.0 µg/dl. In those 18 subjects, baseline and LDC-stimulated DHEA and DHEA-S levels were similar to the whole group of patients with impaired HPA function. The molar ratio of cortisol to DHEA did not change with LDC stimulation in normal subjects and those with NL-HPA. In contrast, patients with impaired HPA had a higher baseline cortisol to DHEA molar ratio that increased further with LDC stimulation. CONCLUSIONS: Patients with impaired HPA function have a more severe loss in DHEA secretion than that of glucocorticoids. Measurements of serum DHEA levels during LDC simulation provide additional valuable information that improves the diagnostic accuracy of LDC in patients suspected to have central AI. We recommend the inclusion of DHEA and DHEA-S measurements in the laboratory assessment of HPA function.
Subject(s)
Adrenal Insufficiency/diagnosis , Chemistry, Clinical/standards , Cosyntropin , Dehydroepiandrosterone Sulfate/blood , Dehydroepiandrosterone/blood , Diagnostic Techniques, Endocrine/standards , ACTH-Secreting Pituitary Adenoma/blood , ACTH-Secreting Pituitary Adenoma/complications , ACTH-Secreting Pituitary Adenoma/diagnosis , Adenoma/blood , Adenoma/complications , Adenoma/diagnosis , Adrenal Insufficiency/blood , Adrenal Insufficiency/etiology , Adult , Aged , Chemistry, Clinical/methods , Female , Hormones , Humans , Hydrocortisone/blood , Male , Middle Aged , Prolactinoma/blood , Prolactinoma/complications , Prolactinoma/diagnosis , Reproducibility of ResultsABSTRACT
OBJECT: Although most Rathke cleft cysts (RCCs) remain asymptomatic, some present with compression of surrounding structures and pituitary hormone dysfunction. A rare, but distinct presentation of the RCC includes hemorrhage into the cyst--a presentation that mimics the clinical syndrome of pituitary tumor apoplexy. The objective of this article is to present the authors' experience on the prevalence and the clinical, biochemical, pathological, and imaging characteristics of hemorrhage into an RCC and review published reports on this entity. METHODS: An institutional database for patients with pituitary masses was reviewed and data on cases involving surgery for a subsequently documented RCC were identified. Patients with documented hemorrhage within the RCC were included in the analysis. Documentation included intraoperative visualization of hemorrhage by the surgeon and/or pathological confirmation of hemorrhage within the RCC. The clinical, biochemical, pathological, and imaging characteristics of these patients were extracted from the database. All published data on RCC were also reviewed and confirmed cases of hemorrhage were extracted and included in the review. RESULTS: A total of 11 cases with hemorrhage within an RCC were identified to have been managed at the authors' institution over a 10-year span. This figure represented 20% of all surgically treated cases of RCC from that period. Among published reports, a total of 10 confirmed cases were evaluated. The clinical presentation of patients with hemorrhage within an RCC are classical and include sudden onset of severe headache--or a sudden increase in headache severity--associated with visual disturbances, impairment in pituitary function, and occasionally alterations in mental status. Leakage of the cystic contents into the subarachnoid space can occur rarely and may lead to associated chemical meningitis. There are no known precipitating factors for this phenomenon. The clinical presentation of such patients is difficult to distinguish from that of patients with pituitary tumor apoplexy. However, patients with RCC apoplexy often present with less severe symptoms, have a lower prevalence of pituitary dysfunction, and generally have smaller mass lesions than those with pituitary tumor apoplexy. Management of patients with RCC apoplexy is similar to that of those with pituitary tumor apoplexy. Surgery can provide definitive diagnosis and relief of symptoms and often leads to recovery from hypopituitarism. All patients with this syndrome require long-term follow-up to treat any residual sequelae. CONCLUSIONS: This article provides the first thorough review and characterization of patients with hemorrhage within an RCC. Based on the clinical manifestations of this presentation, we recommend using the term "Rathke cleft cyst apoplexy" to describe the syndrome.
Subject(s)
Central Nervous System Cysts/pathology , Intracranial Hemorrhages/pathology , Pituitary Apoplexy/pathology , Pituitary Neoplasms/pathology , Adult , Aged , Central Nervous System Cysts/surgery , Child , Child, Preschool , Databases, Factual , Female , Headache/complications , Humans , Male , Middle Aged , Pituitary Apoplexy/surgery , Pituitary Neoplasms/surgery , Treatment OutcomeABSTRACT
Children with malignancies have low bone mass. Pathways for metabolic bone disease were investigated in children with cancer by concomitantly assessing lifestyle, clinical, and biochemical predictors of bone mass. Forty-one children who were receiving cancer therapy for 61 weeks and 39 controls were studied. Data on lifestyle factors, biochemical and hormonal parameters, dual-energy X-ray absorptiometry bone mass measurements, body composition, and bone age were obtained. Compared with controls, patients had higher weight percentile and fat mass, a 6-month delay in bone age, and lower estradiol levels. They also had higher parathyroid hormone levels and lower bone remodeling markers and bone mass. Age, height, lean mass, fat mass, and bone maturation correlated positively with several bone mass variables, so did serum estradiol, testosterone, and markers of bone remodeling. Conversely, corticosteroids, methotrexate (MTX), and intrathecal therapy negatively correlated with bone mass at the spine and hip (R = -0.33 to 0.40, p < 0.04). In the adjusted analyses, bone maturation, serum osteocalcin level, MTX, and intrathecal therapy were significant predictors of lumbar spine and total body Z-scores, bone maturation accounting for the largest proportion in Z-score variance. Chemotherapy-induced delay in bone maturation and suppression of bone modeling are major pathophysiologic pathways predicting bone mass in children with malignancies.
Subject(s)
Absorptiometry, Photon/methods , Bone Density/physiology , Bone Diseases, Metabolic/diagnosis , Bone Remodeling/physiology , Models, Theoretical , Neoplasms/complications , Bone Diseases, Metabolic/etiology , Child , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Male , Prognosis , Retrospective StudiesABSTRACT
Systemic amyloidosis which is characterized by extracellular deposition of monoclonal immunoglobulin light chains in various organs may be difficult to diagnose at an early stage, especially when the Congo red stain is negative. We describe herein a case of Congo red negative primary amyloidosis associated with Hashimoto thyroiditis. The patient presented with multiple organ involvement suggestive of amyloidosis including heart failure, renal failure, and macroglossia. Serum and urine immunofixation studies were positive for monoclonal chains. Even though a biopsy taken from the enlarged tongue of the patient was negative when stained with Congo red, electron microscopy showed ultrastructural features of amyloid deposition. In conclusion, we are reporting a rare case of primary amyloidosis with a negative Congo red stain associated with Hashimoto thyroiditis.
Subject(s)
Amyloidosis/complications , Hashimoto Disease/etiology , Amyloidosis/blood , Amyloidosis/diagnosis , Edema/pathology , Fatal Outcome , Hashimoto Disease/blood , Hashimoto Disease/diagnosis , Humans , Macroglossia/pathology , Male , Microscopy, Electron , Middle Aged , Purpura/pathology , Tongue/pathology , Tongue/ultrastructureABSTRACT
The endocrine system plays an important role in the adaptation to hypoxia. The aim of this study was to assess the effect of chronic hypoxia on insulin, adiponectin, leptin, and ghrelin levels in a neonatal animal model. Sprague-Dawley rats were placed in a normobaric hypoxic environment at birth. Controls remained in room air. Rats were killed at 2 and 8 weeks of life. Insulin, adiponectin, leptin, and ghrelin were measured. At 2 weeks of life, there was no significant difference in insulin, adiponectin, and leptin levels between the hypoxic and control rats. The only statistically significant difference was found in ghrelin levels, which were lower in the hypoxic group (3.19 +/- 3.35 vs 24.52 +/- 5.09 pg/mL; P < .05). At 8 weeks of life, insulin was significantly higher in the hypoxic group (0.72 +/- 0.14 vs 0.44 +/- 0.26 ng/mL; P < .05) and adiponectin was significantly lower (1257.5 +/- 789.5 vs 7817.3 +/- 8453.7 ng/mL; P < .05). Leptin and ghrelin did not show significant difference in this age group, but leptin level per body weight was higher in the hypoxic group. Finally, we conclude that 2 weeks of continuous neonatal hypoxic exposure leads to a decrease in plasma ghrelin only with no significant change in insulin, adiponectin, and leptin and that 8 weeks of hypoxia leads to a decrease in adiponectin with an increase in insulin despite a significant decrease in weight.
Subject(s)
Adiponectin/blood , Ghrelin/blood , Hypoxia/blood , Insulin/blood , Leptin/blood , Animals , Animals, Newborn , Body Weight , Disease Models, Animal , Female , Hematocrit , Pregnancy , Rats , Rats, Sprague-Dawley , Statistics, NonparametricABSTRACT
Erectile dysfunction (ED) appears to be highly prevalent in diabetic patients (around 50% at 50 years of age) and more severe than in the rest of the population. Its etiology is multifactorial in this subset of patients. ED is highly correlated to multiple vascular risk factors and can be considered as a manifestation of endothelial dysfunction in general, alerting the physician to look at underlying silent coronary bed atherosclerosis. It is also dependent on the poor control of diabetes and on the presence of its chronic complications. Because of the multiple etiologies of ED in diabetics, a multifactorial approach is warranted to get an optimal response in treating such patients: diabetes control, use of phosphodiesterase 5 inhibitors, psychosexual counseling, and choice of antihypertensive medications.